RA0642

antibody from Oursmab

Targeting: RTN4 ASY, KIAA0886, NOGO, NSP-CL

Western blot (Data presented on provider website)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0642

Provider

Oursmab

Product name

Ozanezumab (Biosimilar Reference Antibody) (RTN4)

Antibody type

Monoclonal

Description

Ozanezumab (also known as GSK-1223249) is an investigational, humanized monoclonal antibody that targets neurite outgrowth inhibitor (Nogo-A), a protein primarily expressed in the central nervous system (CNS) that inhibits axonal growth and plasticity. By binding to Nogo-A, ozanezumab aims to neutralize its inhibitory activity, thereby promoting axonal regeneration, sprouting, and functional recovery after neurological injury. It was developed as a neurorestorative therapy for amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), with the goal of slowing disease progression by enhancing neural repair. However, clinical trials in ALS did not demonstrate significant efficacy, and its development has been discontinued.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.